| Nov 12 |
Zenas BioPharma, Inc. GAAP EPS of -$5.02
|
| Nov 12 |
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
|
| Nov 12 |
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
|
| Nov 7 |
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
|
| Oct 22 |
Zenas Bio: Recent IPO With Late-Stage Candidate
|
| Oct 14 |
Opening Day: Another trio of biotech IPOs make Friday debut
|
| Oct 8 |
Zenas started at buy by four banks on lead drug potential
|
| Sep 27 |
Biotech IPOs return as sector recovers after funding overhang
|
| Sep 19 |
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
|
| Sep 13 |
Biotech IPO Shares Climb in Debuts After Deals Upsized
|
